Eric Armentani

Eric Armentani has a diverse background in scientific research and development. Eric is currently working as a Scientist at Bright Peak Therapeutics since February 2020. Prior to this, they worked at Ridgeline Therapeutics as a Scientist I from April 2018 to February 2020.

Before their role at Ridgeline Therapeutics, Eric was a Visiting PhD Student at the IRB Institute of Research in Biomedicine from April 2015 to December 2017. During this time, they focused on studying narcolepsy and its potential autoimmune origins.

Eric also worked as a PhD Student at the Università degli Studi di Genova from January 2014 to December 2017. Their research at the university revolved around understanding the immunoregulatory function of CD56(bright) NK cells in multiple sclerosis (MS) and analyzing their role in healthy subjects and MS patients.

Eric's early research experience includes working as a Junior Research Fellow at ABC: Advanced Biotechnology Center from March 2013 to December 2013.

Eric Armentani earned a Master of Science (MS) in Medical Biotechnology from Università degli Studi di Genova. Eric completed this program from 2007 to 2012, focusing their studies on medical biotechnology.